RYR2-Related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1): Comprehensive Research Report

1. Disease Information

Overview. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited primary arrhythmia syndrome ("channelopathy") characterized by exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia (VT) in individuals with a structurally normal heart and a normal resting electrocardiogram. It is one of the most lethal of the inherited arrhythmia syndromes if untreated, with syncope, cardiac arrest, or sudden cardiac death (SCD) — sometimes as the first manifestation — occurring characteristically during physical exertion or acute emotional stress (GeneReviews, NBK1289, updated 2022; PMID:20301466).

Key identifiers: - OMIM (phenotype): CPVT1, #604772 (with or without atrial dysfunction and/or dilated cardiomyopathy) — RYR2-related - OMIM (gene): RYR2 180902 - Related OMIM subtypes: CPVT2 #611938 (CASQ2, gene 114251); CPVT3 #614021 (TECRL, gene 617242); CPVT4 #614916 (CALM1, gene 114180); CPVT5 #615441 (TRDN, gene 603283); CPVT6 #618782 (CALM3, gene 114183) - Orphanet: ORPHA3286 (Catecholaminergic polymorphic ventricular tachycardia) - MONDO: MONDO:0011001 (catecholaminergic polymorphic ventricular tachycardia 1) is the RYR2-specific entity beneath the broader CPVT grouping term; MONDO integrates OMIM/Orphanet/ICD mappings for the umbrella and per-gene subtypes. - ICD-10: I47.2 (Ventricular tachycardia, unspecified — CPVT has no dedicated ICD-10 code and is typically captured under this or I49.0) - MeSH: Tachycardia, Ventricular (D017180); no CPVT-specific MeSH descriptor - HPO: HP:0004758 (Paroxysmal ventricular tachycardia) / HP:0004756 (bidirectional ventricular tachycardia, if modeling that specific ECG pattern); HP:0001279 (Syncope); HP:0001645 (Sudden cardiac death)

Synonyms: CPVT; Familial polymorphic ventricular tachycardia; Bidirectional ventricular tachycardia (historical, for the classic ECG pattern); Catecholamine-induced polymorphic ventricular tachycardia; "Stress-induced polymorphic ventricular tachycardia."

Evidence basis: Information is derived predominantly from aggregated disease-level resources — multicenter clinical registries (e.g., the PACES CPVT registry, PMID for multi-genetic-variant analysis PMC6221297), GeneReviews expert consensus, systematic reviews/meta-analyses of published cohorts, ClinVar/gnomAD population variant databases, and mechanistic studies in iPSC-cardiomyocytes and animal models — rather than from a single large EHR-based cohort, reflecting the disease's rarity.

2. Etiology

Disease Causal Factors. CPVT is purely genetic/mechanistic in etiology — a primary "electrical disease" of cardiomyocyte Ca²⁺ handling, with no infectious or classic environmental causal factor. The disease is triggered (not caused) by adrenergic surges (exercise, acute emotion, occasionally auditory stimuli or fever).

Genetic Risk Factors: - RYR2 (autosomal dominant, gain-of-function): causal in ~50–65% of clinically diagnosed CPVT (estimates range 50–70% across cohorts) (GeneReviews NBK1289; PMID:38542006). - CASQ2 (autosomal recessive, loss-of-function): ~2–5% of cases (CPVT2, OMIM #611938). - TRDN (autosomal recessive): <1–5% of cases (CPVT5). - CALM1/CALM2/CALM3 ("calmodulinopathy," predominantly de novo, autosomal dominant): <1–2% combined; produce a mixed LQTS/CPVT/overlap phenotype (PMID review, Tandfonline 2023). - TECRL (autosomal recessive): CPVT3, rare, combined CPVT/QT-prolongation phenotype. - KCNJ2: rare, associated with some CPVT-like presentations distinct from classic Andersen-Tawil syndrome. - Roughly ~25% of clinically diagnosed CPVT patients remain genetically unsolved after comprehensive panel testing (GeneReviews NBK1289). - De novo RYR2 variants account for an estimated 30–40% of RYR2-CPVT cases (no prior family history) (GeneReviews).

Environmental/Demographic Risk Factors: - Age: mean onset 7–12 years (childhood/adolescent onset is typical, though cases up to age 40 are reported). - Sex: male sex is a risk factor for earlier symptom onset and syncope/cardiac events in RYR2-CPVT — relative risk of syncope ~4.2 in men vs. women in some cohort analyses. - Physical exertion and competitive sports are the principal environmental precipitants; emotional stress is a secondary trigger. - Digitalis/digoxin is a specific pharmacologic risk factor — it favors DAD-mediated triggered arrhythmia and is explicitly listed as an agent to avoid.

Protective Factors: - No specific protective genetic variants are established; some RYR2 missense variants show markedly incomplete penetrance (a recent Bayesian penetrance-modeling study — medRxiv 2025.03.20.25324327 / PMC13108506 — reclassified variant risk using structural + population data), implying that certain domains/positions confer lower phenotypic risk even when "pathogenic" by ACMG criteria. - Nonselective beta-blockade (nadolol) is the major modifiable protective intervention (pharmacologic, not innate). - CYP2D6 pharmacogenetic variation affects propranolol clearance/efficacy (sex-dimorphic; testosterone upregulates CYP2D6, causing faster clearance/lower efficacy in men, partially explaining sex-based outcome differences).

Gene-Environment Interactions: The central GxE axis in CPVT is genotype (RyR2 leak threshold) × sympathetic/adrenergic state (exercise, emotion, occasionally fever). Beta-adrenergic stimulation via PKA/CaMKII phosphorylation of RyR2 lowers the store-overload-induced Ca²⁺ release (SOICR) threshold in already-destabilized mutant channels, converting a subclinical molecular lesion into life-threatening arrhythmia only under catecholamine surge — i.e., the genetic lesion is necessary but adrenergic environmental triggering is required for clinical events. A recent biorxiv 2025 preprint on CaMKII phosphorylation of RYR2 (2025.09.15.676430) reinforces CaMKII-dependent phosphorylation as "essential for arrhythmia in CPVT," a specific molecular GxE node.

3. Phenotypes

Age of onset: Mean 7–12 years; documented range from infancy (occasionally presenting as unexplained SIDS-associated RYR2 variants) to age 40. Severity/progression: Highly variable expressivity — some RYR2 carriers remain asymptomatic lifelong (~50% of mutation carriers per some series, reflecting incomplete penetrance), while others present with SCD as the sentinel event. Course is typically stable-to-episodic under treatment; without treatment, risk of events accumulates with age and continued exposure to exertional/emotional triggers, described as "80% cumulative cardiac events by age 40 if untreated" in some series. Quality of life: Activity restriction (competitive-sports contraindication) is the dominant QoL burden in children/adolescents; psychological burden of living with SCD risk and, in the neurodevelopmental subgroup, cognitive/behavioral impact are documented but not yet formally quantified with SF-36/EQ-5D instruments in the literature reviewed.

4. Genetic/Molecular Information

Causal gene: RYR2 (HGNC:10484; chromosome 1q43), encoding cardiac ryanodine receptor 2 (RyR2), the principal Ca²⁺-release channel of the sarcoplasmic reticulum (SR) in cardiomyocytes.

Variant landscape: - CPVT-causing RYR2 variants are overwhelmingly missense, clustering in defined "hotspot" domains: N-terminal domain (~aa 77–466), central domain (~aa 2246–2534), and the C-terminal channel/transmembrane and RyR/IP3R-homology-associated domains (~aa 3949–4332 and 4867–4967) (Nature/J Hum Genet PMID underlying s10038-020-0738-6; recent structural-penetrance paper PMC13108506/medRxiv 2025.03.20.25324327). - A large aggregation study identified 1,014 affected heterozygotes carrying 468 unique RYR2 missense variants among 622,575 total heterozygotes/5,181 unique variants pooled from literature and gnomAD, underscoring the scale of variant heterogeneity (medRxiv 2025.03.20.25324327). - Population frequency: pathogenic RYR2 CPVT variants are individually very rare in gnomAD (example cited frequency ~3/249,018 chromosomes, ~0.0012%), consistent with a highly penetrant Mendelian disease-gene model, though ACMG reclassification efforts have found meaningful false-positive rates — one systematic re-review of 326 RYR2 missense variants reclassified 55 (16.9%) of previously disease-associated variants as benign/likely benign using 2015 ACMG/AMP criteria. - Functional consequence: The dominant mechanism is gain-of-function — mutant RyR2 channels show increased open probability and heightened sensitivity to luminal/cytosolic Ca²⁺ activation, lowering the threshold for store-overload-induced Ca²⁺ release (SOICR) and producing diastolic SR Ca²⁺ leak. Rare loss-of-function RYR2 variants have also been described, producing a distinct phenotype of exertional syncope/ventricular fibrillation without inducible bidirectional VT on stress testing (Circ Arrhythm Electrophysiol, PMID for "Human RyR2 Loss-of-Function Mutations," CIRCEP.121.010013). - Germline, not somatic: CPVT is a germline Mendelian channelopathy; there is no COSMIC/somatic association. - Modifier genes: No robustly established modifier genes beyond the disease genes themselves; CaMKII-mediated phosphorylation status of RyR2 is a key post-translational/regulatory modifier of arrhythmic risk (biorxiv 2025.09.15.676430).

Recessive/other subtype genes: - CASQ2 (HGNC:1512; calsequestrin-2): loss-of-function, reduced Ca²⁺-buffering capacity and destabilized RyR2 macromolecular complex; 100% penetrant when biallelic; compound heterozygous CASQ2 variants reported with variable long-term course (PMID:29178653). - TRDN (HGNC:12261; triadin): recessive, reduces CASQ2 levels and impairs coupled Ca²⁺ release; may present with mild skeletal myopathy and T-wave inversions/QT prolongation (atypical CPVT). - CALM1/2/3 (calmodulin, HGNC:1442/1848/1849): identical protein product from 3 genes; reduced Ca²⁺-binding affinity impairs regulatory interactions with both CaV1.2 (→ LQTS phenotype) and RyR2 (→ CPVT-like phenotype). CALM-variant carriers present with LQTS (49%), CPVT (28%), overlap LQTS/CPVT (4%), or idiopathic VF/SUD in the remainder (Tandfonline 2023 review). - TECRL (trans-2,3-enoyl-CoA reductase-like): recessive, elevated diastolic Ca²⁺ and impaired mitochondrial function, combined CPVT+QT-prolongation phenotype (CPVT3, OMIM #614021).

Epigenetic information: No disease-defining epigenetic mechanism has been established for CPVT; the disorder is a classical monogenic ion-handling channelopathy.

Chromosomal abnormalities: Not applicable — CPVT is caused by point/small indel variants, not large structural/chromosomal rearrangements.

5. Environmental Information

• Environmental/toxic factors: No toxin, pollutant, or occupational exposure is implicated as causal; digitalis/digoxin is the principal pharmacologic environmental risk modifier (arrhythmia-promoting via DAD mechanism) and is explicitly listed as an agent to avoid.
• Lifestyle factors: Competitive/strenuous exercise and intense emotional stress are the dominant modifiable triggers — activity restriction is a cornerstone of management, not merely correlative.
• Infectious agents: None established as causal; some cohorts note fever as an occasional non-adrenergic trigger context, but this is not a primary infectious mechanism.

6. Mechanism / Pathophysiology

Causal chain (RYR2 gain-of-function, CPVT1):

1. Trigger: Sympathetic/adrenergic activation (exercise, emotion) → PKA and CaMKII phosphorylation of RyR2 and associated Ca²⁺-handling machinery.
2. Molecular lesion: Gain-of-function RYR2 missense variant destabilizes the closed-state conformation of the channel (disrupted N-terminal/central-domain interdomain interactions), lowering the SR luminal Ca²⁺ threshold required for spontaneous store-overload-induced Ca²⁺ release (SOICR) (PMC10311407 — "RYR2-ryanodinopathies: from calcium overload to calcium deficiency," EP Europace 2023).
3. Cellular consequence: Diastolic SR Ca²⁺ leak generates spontaneous, propagating intracellular Ca²⁺ waves in cardiomyocytes.
4. Electrophysiological consequence: Leaked cytosolic Ca²⁺ is extruded via the electrogenic Na⁺/Ca²⁺ exchanger (NCX, 3 Na⁺ in : 1 Ca²⁺ out), generating a net inward depolarizing current that manifests as a delayed afterdepolarization (DAD).
5. Arrhythmia trigger: When DAD amplitude reaches action-potential threshold, it triggers an ectopic beat; when this occurs from distinct/alternating ventricular foci (often Purkinje-adjacent) under ongoing adrenergic drive, the result is the classic bidirectional or polymorphic ventricular tachycardia, which can degenerate into ventricular fibrillation and sudden cardiac death (PMC6928245, PMC2704947).
6. A recent 2025 study specifically demonstrates that subthreshold DADs can still disrupt ventricular activation patterns even without reaching full AP threshold, broadening the arrhythmogenic mechanism beyond simple triggered-beat generation (PMC12221671, RyR2-R420Q model).

Cell types involved: Ventricular and Purkinje-fiber cardiomyocytes (primary); a growing body of evidence also implicates hippocampal/neocortical neurons, since RyR2 is the dominant RyR isoform in brain and its dysregulation is mechanistically linked to a neurodevelopmental/neurocognitive phenotype in a subset of RYR2-CPVT patients (Nature Communications Biology PMC/s42003-022-03124-2; Circ Arrhythm Electrophysiol 2024 CIRCEP.124.013437 reporting ~8% ID prevalence in 421 CPVT1 patients; medRxiv 2025.07.26.25332119 linking RyR2 calcium leak in patient-derived neurons to autism spectrum features). This has prompted a proposed reframing of CPVT as a "neurocardiac" condition in recent literature (biorxiv 2025.01.27.635037).

Suggested GO terms: - GO:0014808 (release of sequestered calcium ion into cytosol by sarcoplasmic reticulum) - GO:0086005 (ventricular cardiac muscle cell action potential) - GO:0086027 (SR-sarcolemma junction organization/ calcium release channel activity) - GO:0005219 (ryanodine-sensitive calcium-release channel activity) - GO:0002026 (regulation of the force of heart contraction)

Suggested CL terms: - CL:0002131 (cardiac ventricle myocyte) - CL:0002355 (cardiac Purkinje myocyte) - CL:0000540 (neuron) — for the emerging neurocardiac arm

Protein dysfunction: Gain-of-function conformational destabilization (not aggregation/misfolding in the classic proteotoxic sense) — mutant RyR2 favors a "leaky," hyperactive closed-to-open transition, well characterized by cryo-EM structural studies of specific CPVT mutants (e.g., R2474S) showing altered channel-gate conformations.

Metabolic changes: RyR2 is also expressed in pancreatic beta cells; altered glucose metabolism has been reported in some RYR2 carriers (GeneReviews NBK1289), an emerging but non-cardiac metabolic association.

Biochemical abnormality: The core lesion is an ion-channel (Ca²⁺ release channel) gating defect — a "channelopathy" in the strict sense, not an enzyme deficiency.

Advanced/omics findings: iPSC-cardiomyocyte disease modeling is the dominant functional-genomics platform for RYR2-CPVT (used extensively for drug screening — e.g., EL20 RyR2 inhibitor, PMC8366453). Structural cryo-EM reconstructions of mutant RyR2 channels (e.g., R2474S) directly visualize altered channel-gate conformations relative to wild-type.

7. Anatomical Structures Affected

• Organ level (primary): Heart — specifically ventricular myocardium and the cardiac conduction/Purkinje system; the heart is structurally normal by imaging (echocardiography/MRI), the defect being purely electrical.
• Secondary organ involvement: Brain (neurodevelopmental/cognitive phenotype in a subset of RYR2 patients); pancreas (beta-cell RyR2 expression, glucose-handling changes in some carriers); skeletal muscle (mild myopathy reported in TRDN-related CPVT).
• Body systems: Cardiovascular (primary); nervous system (emerging secondary/neurocardiac axis); endocrine/metabolic (minor, glucose handling).
• Tissue/cell level: Cardiac muscle tissue — ventricular cardiomyocytes and Purkinje fibers are the principal arrhythmogenic substrate (CL:0002131, CL:0002355); hippocampal and neocortical neurons for the neurologic phenotype.
• Subcellular level: Sarcoplasmic reticulum (GO:0005791/0033017 — SR membrane and junctional SR), specifically the RyR2 Ca²⁺-release channel complex at the SR-sarcolemma dyad/triad junction, and its regulatory partners FKBP12.6 (calstabin2), calsequestrin-2, triadin, and junctin.
• UBERON terms: UBERON:0002082 (cardiac ventricle); UBERON:0002080 (heart); UBERON:0001884 (Purkinje fiber); UBERON:0002421 (hippocampal formation).
• Lateralization: Not applicable — disease is a diffuse/bilateral electrical/molecular process affecting the whole ventricular myocardium, not a focal/lateralized lesion. (LCSD, notably, is performed unilaterally — usually left-sided — as a therapeutic intervention rather than reflecting disease lateralization.)

8. Temporal Development

• Onset: Typically pediatric/adolescent — mean age 7–12 years; documented range from infancy (occult RYR2 variants implicated in some SIDS cases) through age 40. Onset pattern is typically acute/paroxysmal (a syncopal or cardiac-arrest event), rather than insidious.
• Progression: Disease "stage" is not formally classified (unlike cancer staging), but clinical severity is tracked longitudinally via serial exercise stress testing and Holter monitoring; a 2025 medRxiv study specifically examined long-term serial exercise stress testing in CPVT patients on beta-blocker + flecainide therapy, showing the disease course and arrhythmia burden can be tracked and is modifiable by combination pharmacotherapy over years of follow-up.
• Progression rate/course: Without treatment, risk of life-threatening events accumulates with continued exposure to triggers (cumulative event rates reported as high as ~80% by age 40 in some untreated series); with beta-blocker ± flecainide therapy, the disease course is typically stabilized, though breakthrough events can still occur, particularly around puberty (dose titration to weight is emphasized) and with poor treatment adherence.
• Duration: Chronic, lifelong condition — there is no spontaneous resolution; the risk persists across the lifespan though relative event rates are highest in childhood/adolescence and young adulthood.
• Remission patterns: No spontaneous remission is described; symptomatic "remission" (arrhythmia suppression) is treatment-induced via beta-blockade, flecainide, LCSD, or combinations — assessed by serial provocative stress testing.
• Critical periods: Puberty is repeatedly flagged in the literature as a critical vulnerability window requiring more frequent surveillance and dose re-titration owing to rapid weight/body-composition change affecting drug dosing.

9. Inheritance and Population

Epidemiology: - Prevalence: Estimated at approximately 1 in 10,000 individuals (frequently cited range 1:10,000–1:15,000), though true prevalence is likely underestimated because patients have normal resting ECG and normal cardiac imaging, making ascertainment difficult except after a sentinel arrhythmic event or targeted family cascade screening. - Incidence data: No robust population-based incidence rate is established given underdiagnosis; the disease is best characterized via registry-based prevalence and familial-cascade detection.

Inheritance patterns: - Autosomal dominant: RYR2, CALM1, CALM2, CALM3, KCNJ2 — each affected parent transmits with 50% risk per offspring. - Autosomal recessive: CASQ2, TRDN, TECRL — 25% recurrence risk per sibling, 50% carrier risk. - De novo RYR2 variants explain an estimated 30–40% of RYR2-CPVT cases lacking family history.

Penetrance: - RYR2: Mean penetrance estimated at ~83% in some series, but with wide variant-to-variant heterogeneity; approximately 50% of mutation carriers may remain entirely asymptomatic, reflecting substantial incomplete/variable penetrance — a 2025 Bayesian structural-modeling paper specifically develops continuous, variant-level penetrance estimates for RYR2-CPVT missense variants rather than a single point estimate (PMC13108506/medRxiv 2025.03.20.25324327). - CASQ2 (biallelic): ~100% penetrant. - Heterozygous CASQ2 carriers may show a mild/subclinical phenotype. - Insufficient case numbers exist to derive robust penetrance estimates for CALM, KCNJ2, TRDN, and TECRL variants (GeneReviews NBK1289).

Expressivity: Variable — even within families carrying the identical RYR2 variant, phenotype severity ranges from asymptomatic to sudden death, and there is documented sex-based expressivity divergence (see below).

Genetic anticipation: Not a recognized feature of CPVT (not a repeat-expansion disorder).

Founder effects: The best-documented founder mutation is the Finnish RyR2-P2328S variant, traced by genealogical analysis to a common ancestor couple in central Finland in the 17th–18th century (PMC7735638). Other population-specific variant clusters have been reported (e.g., in Kazakh and Chinese cohorts) though without formal founder-effect confirmation in the sources reviewed.

Consanguinity: Relevant specifically for the recessive subtypes (CASQ2, TRDN, TECRL), where consanguineous unions increase biallelic-variant risk, consistent with general autosomal recessive disease principles.

Carrier frequency: Population carrier frequency of any single pathogenic RYR2 variant is very low (individual variant frequencies on the order of 0.001–0.01% in gnomAD), consistent with high aggregate genetic heterogeneity (>460 unique disease-associated missense variants described) rather than one or a few common alleles.

Population demographics: - No strong ethnic-specific prevalence enrichment is described beyond the Finnish founder cluster; the disease has been reported across European, East Asian (Chinese systematic review, PMC9330865), Central Asian (Kazakh cohort), and other populations. - Sex ratio: Not markedly skewed in genetic prevalence, but clinical expressivity is sex-dimorphic — males show earlier symptom onset and higher relative risk of syncope/cardiac events (RR ~4.2 in some analyses), partly attributable to CYP2D6-mediated sex differences in beta-blocker (propranolol) pharmacokinetics (testosterone-driven CYP2D6 upregulation → faster clearance/lower drug exposure in males). - Age distribution: Predominantly diagnosed in childhood/adolescence/young adulthood; a minority present later (up to age 40).

10. Diagnostics

Clinical diagnostic criteria (GeneReviews NBK1289; consensus HRS/EHRA/APHRS and ESC criteria): CPVT is diagnosed when there is (a) a structurally normal heart on imaging, (b) a normal resting ECG, and (c) exercise- or emotion-induced bidirectional or polymorphic VT; OR when a heterozygous pathogenic variant is found in RYR2/CALM1/CALM2/CALM3/CASQ2/KCNJ2, or biallelic variants in CASQ2/TECRL/TRDN.

Exercise stress testing: The primary provocative test — arrhythmia (PVCs progressing to bigeminy, couplets, then sustained bidirectional/polymorphic VT) typically emerges at a heart rate threshold of 90–120 bpm, with progressively increasing complexity as workload increases; positive in up to ~80% of symptomatic patients.

Epinephrine (catecholamine) challenge: Used when exercise testing is not feasible (young children) or symptoms are emotion-triggered. Standard protocol: incremental epinephrine infusion starting at 0.05–0.1 mcg/kg/min, increasing by 0.05 mcg/kg/min increments to a maximum of 0.20 mcg/kg/min; test is positive with induction of sustained/non-sustained polymorphic VT (>10 PVCs/min) or new T-wave alternans. Compared to exercise testing, epinephrine challenge has low sensitivity (~28%) but high specificity (~98%).

Holter monitoring: Alternative/complementary method, particularly for very young patients or emotion-triggered (non-exertional) presentations.

Genetic testing: Multigene panel (RYR2, CASQ2, CALM1-3, TRDN, TECRL, KCNJ2) or exome/genome sequencing is recommended as first-tier molecular testing; sequence-analysis detection sensitivity approaches 99–100% for most genes, though ~25% of clinically diagnosed patients remain molecularly unsolved. ACMG/AMP-based reclassification efforts have found meaningful rates of prior misclassification (16.9% of previously "disease-associated" RYR2 missense variants reclassified benign in one study), underscoring the importance of rigorous variant curation (ClinVar cross-checking, structural/functional evidence, penetrance modeling).

Imaging: Echocardiography and cardiac MRI are used primarily to exclude structural heart disease (e.g., ARVC, cardiomyopathy) rather than to positively diagnose CPVT; performed at baseline and roughly every 2 years during surveillance.

Differential diagnosis: - Short-coupled Torsade de Pointes (SC-TdP): polymorphic VT not clearly adrenergically triggered and lacking the bidirectional pattern; no established effective CPVT-type therapy. - Long QT syndrome type 1 (LQT1): exercise-triggered syncope overlaps clinically, but LQT1 shows a prolonged QT interval and does not reproduce inducible bidirectional VT on graded exercise testing (unless overlap calmodulinopathy). - Arrhythmogenic right ventricular cardiomyopathy (ARVC): shows structural myocardial abnormality on imaging, distinguishing it from CPVT's structurally normal heart. - Idiopathic ventricular fibrillation: relevant differential for RYR2 loss-of-function variant carriers, who may present with VF without the classic inducible bidirectional VT pattern.

Screening: Cascade family screening (clinical + genetic) is standard once a proband is identified, given up to 50% first-degree-relative transmission risk (dominant genes) and family history present in ~30% of probands.

11. Outcome/Prognosis

• Untreated mortality: Historically cited untreated mortality figures range widely across sources — approximately 30–50% by age 30–35, with some series reporting cardiac event rates as high as 80% by age 40 if untreated; approximately 30% experience cardiac arrest and up to 80% experience syncope if untreated (GeneReviews NBK1289).
• With treatment: Beta-blocker therapy (particularly nadolol) substantially reduces mortality and arrhythmic events; combination therapy (beta-blocker + flecainide ± LCSD/ICD) further reduces breakthrough events, as demonstrated in long-term serial-stress-testing follow-up cohorts (medRxiv 2025.04.08.25325493).
• Morbidity: Beyond mortality, morbidity includes recurrent syncope, ICD-related complications (inappropriate/ineffective shocks, which can paradoxically worsen VT storm via further adrenergic surge), and — in the RYR2-neurodevelopmental subgroup — intellectual disability and behavioral impact.
• Prognostic factors: Genotype (RYR2 vs. CASQ2 vs. calmodulinopathy), specific variant/domain location and structural severity (informing the new Bayesian penetrance models), sex (male sex worse), age at first event, and treatment adherence/response on serial exercise testing are the principal prognostic determinants identified in the literature. No single validated prognostic biomarker (analogous to a cancer biomarker) exists; risk stratification instead relies on genotype, clinical/family history, and provocative testing response.
• ICD-specific risk: ICDs are a double-edged prognostic tool in CPVT — while indicated in drug-refractory, highly symptomatic disease, inappropriate or even appropriate shocks can trigger further catecholamine release, precipitating an electrical storm; this is a well-recognized complication specific to this disease's adrenergic-arrhythmia mechanism.

12. Treatment

Pharmacotherapy (first-line): - Beta-blockers — nonselective agents preferred over cardioselective ones. Nadolol (1–2.5 mg/kg/day) is considered possibly superior; propranolol (2–4 mg/kg/day, divided) is a common alternative. NCIT: Pharmacotherapy (NCIT:C15986); therapeutic agent nadolol/propranolol (beta-adrenergic antagonists). - Flecainide (Class IC antiarrhythmic; 100–300 mg/day in adults) — added when beta-blockade alone is insufficient; reported effective in suppressing exercise-induced ventricular arrhythmia in ~75% of patients, with effect appearing largely independent of underlying genotype. NCIT: Chemotherapy is not applicable; use NCIT:C15986 Pharmacotherapy with therapeutic_agent flecainide (CHEBI).

Advanced/emerging therapeutics: - RyR2-targeted small molecules ("Rycals" and related stabilizers): JTV519 (K201) and S107 stabilize FKBP12.6 (calstabin2) binding to RyR2, reducing diastolic Ca²⁺ leak; dantrolene (a hydantoin derivative, historically a malignant-hyperthermia drug) has been repurposed and shown in iPSC-cardiomyocyte studies to reduce ectopic beats in a mutation/domain-dependent manner — more effective for N-terminal and central-domain RyR2 mutations than transmembrane-domain mutations, consistent with its proposed mechanism of stabilizing the N-terminal/central-domain interaction. Newer tetracaine-derivative RyR2 inhibitors (EL9, EL20) have shown efficacy in patient-derived iPSC-cardiomyocyte models (PMC8366453). A novel RyR2-selective stabilizer preventing stress-induced arrhythmia was reported in a 2024/2025 preprint (biorxiv 2024.11.26.625386). - Gene therapy: Solid Biosciences' AAV-based gene therapy candidate SGT-501 for CPVT began its first-in-human Phase 1b study in May 2024, an open-label trial enrolling approximately 43 patients aged 4–11 years — the first gene-therapy clinical trial specifically for CPVT (CGTlive, 2024). NCIT: Gene Therapy (NCIT:C15238).

Surgical/interventional: - Left cardiac sympathetic denervation (LCSD): Recommended as an adjunct in young patients not fully protected by beta-blockade, or when patients fail combination beta-blocker + flecainide therapy; also used to reduce ICD shock burden. Side effects include Horner-type ptosis and facial/arm anhidrosis. NCIT: Surgical Procedure (NCIT:C15329) or a sympathectomy-specific NCIT code if available. - Implantable cardioverter-defibrillator (ICD): Indicated in drug-refractory, highly symptomatic disease; use requires caution given the risk that shocks (appropriate or inappropriate) can provoke further catecholamine release and precipitate electrical storm, a distinctive management challenge in this specific arrhythmia syndrome. NCIT: Device (implantable cardioverter-defibrillator implantation).

Supportive/behavioral: - Absolute avoidance of competitive sports and strenuous exercise; activity restriction counseling. NCIT:C181743 (Behavioral Counseling) / therapeutic_modality: BEHAVIORAL. - Avoidance of digitalis/digoxin (arrhythmia-promoting). - Atropine has been studied experimentally in CPVT (registered trial NCT02927223) though it is not standard therapy and its precise role remains investigational.

Genetic counseling: Family cascade testing and counseling given 50% (dominant) or 25% (recessive) transmission risk; recommended given the potential for sudden death as first manifestation in unrecognized carriers.

Treatment algorithm (stepwise): (1) Beta-blocker (nadolol preferred) for all clinically affected individuals and asymptomatic pathogenic-variant carriers → (2) add flecainide if breakthrough arrhythmia on stress testing/symptoms → (3) LCSD and/or ICD if still refractory, with LCSD often favored first given the risk of ICD-triggered arrhythmic storms → (4) gene therapy (SGT-501) and novel RyR2 stabilizers under active clinical investigation as of 2024–2025.

13. Prevention

• Primary prevention: Not applicable in the classic sense (no modifiable non-genetic cause to prevent onset), but pre-symptomatic beta-blocker initiation in genotype-positive, phenotype-negative relatives identified through cascade screening functions as a primary preventive strategy against the first (potentially fatal) event.
• Secondary prevention: Family cascade genetic screening after proband identification; periodic exercise stress testing surveillance (every 6–12 months, more frequent during puberty) to detect breakthrough arrhythmia before a clinical event.
• Tertiary prevention: ICD implantation and LCSD in patients with established, drug-refractory disease to prevent recurrent/fatal events; combination pharmacotherapy adjustment based on serial stress-test results.
• Screening: No population-based newborn screening exists (CPVT is not detectable on a resting ECG); screening is instead cascade/family-based following proband diagnosis, using multigene panel testing.
• Genetic counseling: Central to prevention — informing reproductive decisions and triggering early beta-blocker initiation in asymptomatic carriers.
• Behavioral/public health intervention: Activity restriction guidance (avoidance of competitive sports) issued through cardiology/sports-cardiology clinical guidelines is the principal behavioral prevention lever.
• Prophylaxis: Prophylactic beta-blockade in all genotype-positive individuals regardless of symptom status is explicitly recommended in GeneReviews given the risk of sudden death as the first manifestation.

14. Other Species / Natural Disease

• Taxonomy: RYR2 orthologs are highly conserved across vertebrates (NCBI Taxon 9606 human; conserved in Mus musculus NCBITaxon:10090, Danio rerio NCBITaxon:7955, Sus scrofa NCBITaxon:9823, Ovis aries NCBITaxon:9940).
• Gene orthologs: Mouse Ryr2 (NCBI Gene: 20191); highly conserved functional domains across species enable cross-species modeling.
• Naturally occurring disease in other species: No well-established naturally occurring CPVT/RYR2 disease model was identified in dogs via OMIA in this search (the related but mechanistically distinct Boxer-dog arrhythmogenic right ventricular cardiomyopathy is caused by a STRN variant, not RYR2, and was historically — and now understood to be incorrectly — attributed in part to calstabin2/FKBP12.6 deficiency in earlier literature). No confirmed naturally occurring veterinary CPVT phenotype driven by spontaneous RYR2 variants was found in the searched sources.
• Comparative biology: The RyR2-mediated Ca²⁺-leak/DAD arrhythmia mechanism is evolutionarily conserved and reproducible across engineered animal models (mouse, zebrafish, pig, sheep), supporting strong translational validity of the induced (non-natural) models described below.
• Zoonotic potential: Not applicable — CPVT is a non-infectious, purely genetic disease with no transmission risk.

15. Model Organisms

Mouse models (most extensively characterized): - RyR2-R4496C knock-in mouse (corresponding to human R4497C): generated by homologous recombination in a fully penetrant human CPVT family variant; considered "the first RyR2 transgenic mouse model that recapitulates the main aspects of human CPVT" — mice show stress/catecholamine-induced ventricular arrhythmia and sudden death, with cellular studies showing enhanced SR Ca²⁺ release and DAD generation, and structural destabilization favoring a closed-to-open channel transition (leaky channel). - RyR2-P2328S knock-in mouse: models the Finnish founder mutation; shown to downregulate Nav1.5, producing an additional arrhythmic substrate in ventricular tissue (PMC4792352) — illustrating a secondary ion-channel remodeling mechanism beyond the primary RyR2 Ca²⁺-leak defect. - RyR2+/− (haploinsufficient) mouse: exhibits arrhythmogenic phenotypes resembling CPVT, used to model loss-of-function-associated arrhythmia. - Additional knock-in efforts (e.g., attempted Q3924E Ca²⁺-binding-site mutant mice, PMC11674951) illustrate ongoing efforts to model specific structural domains, though not all attempted knock-ins produce viable/faithful models. - Exon-3-deletion RyR2 mouse: models a specific human CPVT-associated exon-skipping/deletion variant (PMC3990712).

Zebrafish models: Used to study CALM-mutation-associated CPVT via overexpression approaches, successfully demonstrating cardiac arrhythmia phenotypes; zebrafish offer high-throughput in vivo screening advantages for CPVT drug discovery given transparent embryos and amenability to genetic manipulation.

Large animal models: Pigs and sheep are increasingly used as large-animal ventricular-arrhythmia models given closer anatomical/physiological resemblance to the human heart than rodents (more ethically/economically favorable than dog models); RYR2-specific engineered large-animal CPVT models are less mature than the mouse literature but are an active area per recent reviews (Biology 2026, 15040343).

Cellular/iPSC models: Patient-derived induced pluripotent stem cell-cardiomyocytes (iPSC-CMs) are now the dominant translational platform for RYR2/CASQ2-CPVT — used to validate calcium-handling defects, screen RyR2-stabilizing compounds (dantrolene, EL20, S107/JTV519 analogs), and, in a 2025 study, to link RyR2 calcium leak in patient-derived neurons to autism-spectrum features, directly bridging the cardiac and emerging neurodevelopmental phenotype (medRxiv 2025.07.26.25332119).

Model limitations: Mouse cardiac electrophysiology differs substantially from human (heart rate, ion channel repertoire), so while Ca²⁺-leak/DAD mechanisms are well recapitulated, absolute arrhythmia thresholds and some pharmacologic responses may not translate directly; iPSC-CM models lack full three-dimensional tissue architecture and autonomic innervation context, limiting their ability to model the whole-organism adrenergic trigger.

Applications: These models have been essential for (1) establishing the core Ca²⁺-leak/DAD mechanistic paradigm, (2) genotype-specific drug screening (e.g., domain-dependent dantrolene efficacy), (3) preclinical validation of RyR2-stabilizer and gene-therapy (AAV-CASQ2/RYR2) approaches prior to human trials such as SGT-501.

Summary of Key Ontology Term Suggestions

Sources

• GeneReviews: Catecholaminergic Polymorphic Ventricular Tachycardia
• Clinical and Molecular Characterization of Patients With CPVT (Priori et al., Circulation 2002)
• RYR2 Variants in CPVT Patients: Insights From Protein Structure and Clinical Data (Circ Arrhythm Electrophysiol 2025)
• RYR2-ryanodinopathies: from calcium overload to calcium deficiency (EP Europace 2023)
• Disruption of ventricular activation by subthreshold DADs in RyR2-R420Q CPVT
• Therapeutic approach for CPVT patients (EP Europace 2012)
• Left cardiac sympathetic denervation for CPVT and LQTS
• Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies (J Clin Med 2024)
• CPVT: Advancing From Molecular Insights to Preclinical Models (JAHA 2024)
• PACES CPVT Registry: multiple genetic variants
• International Multicenter Evaluation of CASQ2-CPVT (Circulation 2021)
• Long-term Serial Exercise Stress Testing in CPVT (medRxiv 2025)
• Structural Evaluation of RYR2-CPVT Missense Variants and Bayesian Penetrance Estimates (2025)
• Classification and correlation of RYR2 missense variants (J Hum Genet)
• Efficacy of RyR2 inhibitor EL20 in iPSC-CMs from a CPVT patient
• Solid Biosciences' CPVT Gene Therapy SGT-501 Phase 1b (CGTlive, 2024)
• Genealogy and clinical course of CPVT caused by RyR2 P2328S (Finnish founder mutation)
• The RyR2-P2328S mutation downregulates Nav1.5
• Calmodulin Mutations in Human Disease (2023 review)
• Intellectual and Neurodevelopmental Delays in Pediatric CPVT (Circ Arrhythm Electrophysiol 2024)
• Linking the heart and the brain: Neurodevelopmental disorders in CPVT (Mayo Clinic)
• Patient-derived cells: mutated RyR2 calcium leak underlies ASD and inherited arrhythmias (medRxiv 2025)
• OMIM #604772 — CPVT1
• OMIM #611938 — CPVT2 (CASQ2)
• Human RyR2 Loss-of-Function Mutations (Circ Arrhythm Electrophysiol)
• Selected Large-Animal Models of Ventricular Arrhythmias (Biology, 2026)
• Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs and calstabin2 deficiency
• CaMKII Phosphorylation of RYR2 is Essential for Arrhythmia in CPVT (bioRxiv 2025)